Collins Stewart Says Buy Alcon (ACL)
Collins Stewart has a research note on Alcon, Inc. (NYSE: ACL), and it has a Buy rating on shares. It has a $180 price target on shares.
In the research note, Collins Stewart writes, "Market share progression of Azarga in EU and launch of DuoTrav in Japan, (2) Launch progression of brimonidine 0.15%, (3) Increased penetration and utilization of the AcrySof IQ Toric and ReSTOR +3.0 in the US, (4) The further development of Laureate phaco system in emerging markets, (5) Near term sales growth driven by ACL's recent business development activities, Optonol and Durezol, (6) New product launches of ReSTOR Toric, TobraDex ST, Systane BALANCE, WaveLight EX-500 & FS-200, And (7) Pipeline advancements (Potentia, AZN collaboration, PhiloGene, ESBATech, moxifloxacin next generation, NVC-422, AcrySof Phakic in the US, Zyclorin, DuoTrav APS (EU filing 2010) and Systane)."
Shares of ACL lost $1.43 yesterday to close at $165.77, a loss of nearly 1%.
